Notes in 5. Multiple myeloma

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.1 \| Description
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.2 \| Epidemiology
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.3 \| Risk factors
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.4 \| Biologic behaviour
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.5.1 \| Macroscopic and microscopic appearance
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.6 \| Clinical presentation
Published	02/18/2024	Haem \| Multiple myeloma \| 2.1 \| Workup
Published	02/18/2024	Haem \| Multiple myeloma \| 0.1 \| Background \| Antibody structure and isotypes
Published	02/18/2024	Haem \| Multiple myeloma \| 1.0 \| Plasma cell dyscrasias - classification
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.7 \| Proteins secreted
Published	02/18/2024	Haem \| Multiple myeloma \| 2.4 \| Diagnostic criteria (International Myeloma Working Group criteria)
Published	02/18/2024	Haem \| Multiple myeloma \| 2.2 \| Serum protein electrophoresis
Published	02/18/2024	Haem \| Multiple myeloma \| 2.3 \| Staging - international myeloma working group  international staging system (ISS)
Published	02/18/2024	Haem \| Multiple myeloma \| 2.5 \| Prognostic factors
Published	02/18/2024	Haem \| Multiple myeloma \| 1.2 \| Solitary plasmacytoma \| Definition, epidemiology, RFs, biological behaviour, clinical presentation, macro and micro pa…
Published	02/18/2024	Haem \| Multiple myeloma \| 1.3 \| Nonsecretory myeloma
Published	02/18/2024	Haem \| Multiple myeloma \| 1.4 \| MGUS
Published	02/18/2024	Haem \| Multiple myeloma \| 1.5 \| Smoldering MM
Published	02/18/2024	Haem \| Multiple myeloma \| 3.1 \| Management overview (MM and solitary plasmacytoma)
Published	02/18/2024	Haem \| Multiple myeloma \| 2.6 \| Role of PET/CT
Published	02/18/2024	Haem \| Multiple myeloma \| 3.2.1 \| Induction chemotherapy, transplant, maintenance systemic therapy
Published	02/18/2024	Haem \| Multiple myeloma \| 3.3 \| Bisphosphanates
Published	02/18/2024	Haem \| Multiple myeloma \| 3.4 \| Radiotherapy
Published	02/18/2024	Haem \| Multiple myeloma \| 3.5 \| Other supportive measures
Published	02/18/2024	Haem \| Multiple myeloma \| 4 \| Follow up
Published	02/18/2024	Haem \| Multiple myeloma \| 5.1 \| Solitary plasmacytoma \| Management
Published	02/18/2024	Haem \| Multiple myeloma \| 5.2 \| Solitary plasmacytoma \| Evidence
Published	02/18/2024	Haem \| Multiple myeloma \| 5.3 \| Solitary plasmacytoma \| Treatment technique
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.5.2 \| Cytogenetic abnormalities
Published	02/18/2024	Haem \| Multiple myeloma \| 3.2.3 \| Monitoring after primary myeloma therapy (for both transplant and non-transplant candidates)
Published	02/18/2024	Haem \| Multiple myeloma \| 3.2.2 \| Stem cell transplants
Published	02/18/2024	Haem \| Multiple myeloma \| 3.2.4 \| Relapsed disease
Published	02/18/2024	Haem \| Multiple myeloma \| 1.1.8 \| Pathophysiology
Status	Last Update	Fields